Literature DB >> 16508703

Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.

M J J Fleury1, A Touzé, E Alvarez, G Carpentier, C Clavel, J-F Vautherot, P Coursaget.   

Abstract

The majority of the neutralizing epitopes of papillomaviruses (PV) are conformation-specific and have not been fully characterised. Studies have, to date, been limited to a few HPV types only. We analysed the epitopes on the major capsid protein (L1) of Human papillomavirus (HPV) type 31 using monoclonal antibodies (MAbs) generated against HPV-31 virus-like particles (VLPs). The type-specific MAbs against HPV-31 were all found to be neutralizing and recognized conformation-dependent epitopes. Two other MAbs directed against a conformational epitope were found to be cross-reactive with other HPV types, and one of them was found to be cross-neutralizing. Cross-reactive antibodies were further investigated using wild-type HPV-16 L1 VLPs and two mutants. The results obtained suggested the existence of a cross-neutralizing conformational epitope at the N-terminal part of the FG loop of the major capsid protein, and the other four cross-reactive MAbs recognized epitopes also located at the N-terminal part of the FG loop.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16508703      PMCID: PMC7086758          DOI: 10.1007/s00705-006-0734-y

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  45 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.

Authors:  Latifa Bousarghin; Alba-Lucia Combita-Rojas; Antoine Touzé; Slimane El Mehdaoui; Pierre-Yves Sizaret; Maria-Mercedes Bravo; Pierre Coursaget
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Immunological analyses of human papillomavirus capsids.

Authors:  T Giroglou; M Sapp; C Lane; C Fligge; N D Christensen; R E Streeck; R C Rose
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

4.  Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes.

Authors:  J Cason; D Patel; J Naylor; D Lunney; P S Shepherd; J M Best; D J McCance
Journal:  J Gen Virol       Date:  1989-11       Impact factor: 3.891

5.  Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11.

Authors:  S W Ludmerer; D Benincasa; G E Mark
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.

Authors:  W I White; S D Wilson; W Bonnez; R C Rose; S Koenig; J A Suzich
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

8.  A controlled trial of a human papillomavirus type 16 vaccine.

Authors:  Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

9.  Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.

Authors:  Alba-Lucia Combita; Antoine Touzé; Latifa Bousarghin; Neil D Christensen; Pierre Coursaget
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.

Authors:  R B Roden; E M Weissinger; D W Henderson; F Booy; R Kirnbauer; J F Mushinski; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

View more
  16 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

3.  Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.

Authors:  Maxime J J Fleury; Antoine Touzé; Pierre Coursaget
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

4.  Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Authors:  Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  Generation of Merkel cell polyomavirus (MCV)-like particles and their application to detection of MCV antibodies.

Authors:  Antoine Touzé; Julien Gaitan; Françoise Arnold; Raphaël Cazal; Maxime J Fleury; Nicolas Combelas; Pierre-Yves Sizaret; Serge Guyetant; Annabel Maruani; Marc Baay; Mauro Tognon; Pierre Coursaget
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

6.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

7.  Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.

Authors:  Nicolas Combelas; Emilie Saussereau; Maxime J J Fleury; Tatiana Ribeiro; Julien Gaitan; Diego F Duarte-Forero; Pierre Coursaget; Antoine Touzé
Journal:  J Transl Med       Date:  2010-03-24       Impact factor: 5.531

8.  Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.

Authors:  Michael Vaine; Shixia Wang; Qin Liu; James Arthos; David Montefiori; Paul Goepfert; M Juliana McElrath; Shan Lu
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

9.  Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

Authors:  Hannah H Alphs; Ratish Gambhira; Balasubramanyam Karanam; Jeffrey N Roberts; Subhashini Jagu; John T Schiller; Weiguang Zeng; David C Jackson; Richard B S Roden
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-14       Impact factor: 11.205

10.  Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.

Authors:  Anna Godi; Dolcibella Boampong; Busayo Elegunde; Kavita Panwar; Maxime Fleury; Shaowei Li; Qinjian Zhao; Ningshao Xia; Neil D Christensen; Simon Beddows
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.